• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma - SUNNIFORECAST AN 41/16 der AUO].

作者信息

Rexer H, Bergmann L, Steiner T

机构信息

AUO Geschäftsstelle, Seestr. 11, 17252 Schwarz,

Leiter der klinischen Prüfung (LKP), Universitätsklinikum Frankfurt, Medizinische Klinik II, Theodor-Stern-Kai 7, 60590 Frankfurt.

出版信息

Aktuelle Urol. 2020 Jun;51(3):236-238. doi: 10.1055/a-1079-7621. Epub 2020 Jun 2.

DOI:10.1055/a-1079-7621
PMID:32485769
Abstract
摘要

相似文献

1
[A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma - SUNNIFORECAST AN 41/16 der AUO].
Aktuelle Urol. 2020 Jun;51(3):236-238. doi: 10.1055/a-1079-7621. Epub 2020 Jun 2.
2
[Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma].纳武利尤单抗联合伊匹木单抗对比舒尼替尼单药治疗——AUO的SUNNIFORECAST AN 41/16：一项针对既往未接受治疗的晚期（不可切除或转移性）非透明细胞肾细胞癌患者的2期随机开放标签研究
Urologe A. 2017 Jun;56(6):802-803. doi: 10.1007/s00120-017-0397-1.
3
Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.纳武利尤单抗联合伊匹单抗与舒尼替尼治疗晚期肾细胞癌的不良事件和成本的时间趋势。
Future Oncol. 2022 Mar;18(10):1219-1234. doi: 10.2217/fon-2021-1109. Epub 2021 Dec 23.
4
A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.纳武利尤单抗联合伊匹单抗与舒尼替尼一线治疗中低危晚期肾细胞癌的成本效果分析。
Oncologist. 2019 Mar;24(3):366-371. doi: 10.1634/theoncologist.2018-0656. Epub 2019 Feb 1.
5
Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于既往未治疗的晚期肾细胞癌：CheckMate 214 研究中日本患者的分析结果，随访时间延长。
Jpn J Clin Oncol. 2020 Jan 24;50(1):12-19. doi: 10.1093/jjco/hyz132.
6
[Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO)].
Urologe A. 2015 Oct;54(10):1443-5. doi: 10.1007/s00120-015-3946-5.
7
European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma.欧洲药品管理局将适应症扩展，纳入纳武利尤单抗（欧狄沃）和伊匹单抗（逸沃）联合免疫治疗癌症药物治疗方案，用于中高危晚期肾细胞癌成人患者。
ESMO Open. 2020 Nov;5(6):e000798. doi: 10.1136/esmoopen-2020-000798.
8
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
9
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于晚期肉瘤样肾细胞癌患者一线治疗的疗效和安全性。
Clin Cancer Res. 2021 Jan 1;27(1):78-86. doi: 10.1158/1078-0432.CCR-20-2063. Epub 2020 Sep 1.
10
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.纳武利尤单抗联合伊匹单抗对比舒尼替尼治疗晚期肾细胞癌患者的患者报告结局（CheckMate 214）：一项随机、III 期试验。
Lancet Oncol. 2019 Feb;20(2):297-310. doi: 10.1016/S1470-2045(18)30778-2. Epub 2019 Jan 15.

引用本文的文献

1
Chromophobe renal cell carcinoma - a rare kidney cancer with limited therapy options: a narrative review.嫌色性肾细胞癌——一种治疗选择有限的罕见肾癌：一篇叙述性综述
BMC Urol. 2025 Jun 2;25(1):147. doi: 10.1186/s12894-025-01816-5.
2
Label-Free SERS of Urine Components: A Powerful Tool for Discriminating Renal Cell Carcinoma through Multivariate Analysis and Machine Learning Techniques.尿液成分的无标记 SERS：通过多元分析和机器学习技术鉴别肾细胞癌的有力工具。
Int J Mol Sci. 2024 Mar 31;25(7):3891. doi: 10.3390/ijms25073891.
3
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
一线治疗成人晚期肾细胞癌：系统评价和网络荟萃分析。
Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.
4
Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.免疫疗法：纳入肾癌管理不断演变的模式及未来前景。
Oncotarget. 2017 Mar 7;8(10):17313-17327. doi: 10.18632/oncotarget.14388.